Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal Melanoma Cell Line 92-1

Area of Science:

• Oncology
• Molecular Biology
• Ophthalmology

Background:

• Uveal melanoma (UM) is a primary intraocular malignancy with poor survival rates for metastatic patients.
• Most UM tumors lack common RAF/RAS mutations, presenting a therapeutic challenge.
• The pan-RAF inhibitor LY3009120 has shown efficacy in various tumor models, including those wild-type for RAF/RAS.

Purpose of the Study:

• To evaluate the antitumor effects of the pan-RAF inhibitor LY3009120 on the 92-1 human UM cell line.
• To assess the impact of LY3009120 on UM cell proliferation, viability, and apoptosis.
• To characterize the mutational landscape of the 92-1 UM cell line.

Main Methods:

• In vitro characterization of LY3009120's effect on cell proliferation, metabolic activity, biomass, apoptosis, and morphology.
• Treatment of 92-1 UM cells with LY3009120 at concentrations ranging from 0.1 to 5 μM for 48 or 72 hours.
• Targeted panel sequencing (Oncomine myeloid panel) to determine the mutational status of 50 genes, including BRAF, NRAS, and KRAS.

Main Results:

• LY3009120 demonstrated a significant, concentration-dependent anti-proliferative effect on 92-1 UM cells.
• Cell proliferation and viability were significantly reduced at 0.5 μM LY3009120 (p<0.001) after 48 and 72 hours.
• LY3009120 induced significant early and late apoptosis/necrosis in 92-1 cells at 5 μM.
• Next-generation sequencing revealed that the 92-1 cell line was wild-type for BRAF, NRAS, KRAS, and 46 other genes, with the exception of TP53.

Conclusions:

• The pan-RAF inhibitor LY3009120 exhibits significant antitumor activity against the 92-1 human UM cell line.
• The observed anti-tumor effect is independent of BRAF and RAS mutational status.
• LY3009120 represents a potential therapeutic agent for UM, irrespective of common driver mutations.